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Abstract
Background: Atherosclerosis is a multifactorial disorder of the heart vessels that develops over decades, coupling
inflammatory mechanisms and elevated total cholesterol levels under the influence of genetic and environmental
factors. Without effective intervention, atherosclerosis consequently causes coronary heart disease (CHD), which
leads to increased risk of sudden death.
Polymorphonuclear neutrophils play a pivotal role in inflammation and atherogenesis. Human neutrophil peptides
(HNPs) or alpha (α)-defensins are cysteine-rich cation polypeptides that are produced and released from activated
polymorphonuclear neutrophil granules during septic inflammation and acute coronary vascular disorders. HNPs
cause endothelial cell dysfunction during early atherogenesis. In this cross-sectional study, control, hyperlipidemia
and CHD groups were representative as atherosclerosis development and CHD complications. We aimed to assess
the correlation between α-defensin expression and the development of CHD, and whether it was a useful
predictive indicator for CHD risk.
Methods: First, DNA microarray analysis was performed on peripheral blood mononuclear cells (PBMCs) from Thai
control, hyperlipidemia and CHD male patients (n = 7). Gene expression profiling revealed eight up-regulated genes
common between hyperlipidemia and CHD patients, but not controls. We sought to verify and compare α-defensin
expression among the groups using: 1) real-time quantitative RT-PCR (qRT-PCR) to determine α-defensin mRNA
expression (n = 10), and 2) enzyme-linked immunosorbent assay to determine plasma HNP 1–3 levels (n = 17).
Statistically significant differences and correlations between groups were determined by the Mann–Whitney U test
or the Kruskal–Wallis test, and the Rho-Spearman correlation, respectively.
Results: We found that α-defensin mRNA expression increased (mean 2-fold change) in the hyperlipidemia
(p = 0.043) and CHD patients (p = 0.05) compared with the controls. CHD development moderately correlated
with α-defensin mRNA expression (r = 0.429, p = 0.023) and with plasma HNP 1–3 levels (r = 0.486, p = 0.000).
Conclusions: Increased α-defensin expression is a potential inflammatory marker that may predict the risk of CHD
development in Thai hyperlipidemia patients.
Keywords: alpha-defensin, HNP 1–3, Neutrophil, CHD, Coronary heart disease, Hyperlipidemia, Biomarker
* Correspondence: yaowapa.man@mahidol.ac.th
1Department of Tropical Pathology, Faculty of Tropical Medicine, Mahidol
University, Bangkok 10400, Thailand
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Maneerat et al. Lipids in Health and Disease  (2016) 15:117 
DOI 10.1186/s12944-016-0285-5
Background
Atherosclerosis is a multifactorial disorder of heart
blood vessels that develops over decades, coupling in-
flammatory mechanisms and dyslipidemia, and resulting
in the formation of atherosclerotic plaques. Atheroscler-
osis develops under the influence of genetic and environ-
mental factors. It is a chronic inflammatory disorder of
the vessel wall, where both innate and adaptive immune
responses influence disease progression [1]. This involves:
impairment of endothelial cell (EC) function; accumula-
tion of cholesterol in subendothelial macrophage-derived
foam cells; adherence and recruitment of leukocytes into
the arterial wall; proliferation and migration of smooth
muscle cells into the intima; activation and aggregation of
platelets; T cell activation; and production of inflammatory
cytokines [2]. The innate signals within the lesion can
arise from various sources and promote atherosclerosis
through inflammatory processes. Oxidized low-density
lipoprotein (LDL) accumulation, starting in the fatty
streaks, promotes the inflammatory response, which most
likely continues throughout lesion development. Further-
more, pathogenic infection and endogenous danger
signals increase during tissue injury and have been impli-
cated as inducers of lesion inflammation. ECs are activated
by accumulation of modified LDL and increase the ex-
pression of adhesion molecules, mainly vascular cell adhe-
sion molecule (VCAM-1) [3]. EC activation occurs
predominantly at atherosclerosis-prone sites with in-
creased hemodynamic strain, leading to infiltration of
monocytes and T cells into the arterial wall [4, 5]. The
recruitment of immune cells is a critical early step in ath-
erosclerosis development and is potentiated by local
chemokine release. Monocyte chemotactic protein-1
(MCP-1) appears to be particularly essential for attracting
monocytes, whereas T helper type 1 (Th1) cells are re-
cruited to the lesion by production of regulated upon acti-
vation, normal T cell expressed and secreted (RANTES),
interferon inducible protein (IP)-10 and interferon-
inducible T cell alpha chemoattractant (I-TAC) [6–9]. The
infiltrated cells further increase local inflammation
through production of several cytokines that increase re-
cruitment and activation of additional immune cells.
Monocytes differentiate into macrophages in the presence
of macrophage colony-stimulating factor (M-CSF) pro-
duced in lesions by ECs and smooth muscle cells. This is a
crucial step in atherogenesis and is accompanied by up-
regulation of innate immune receptors required for
phagocytosis and induction of inflammatory processes [6].
Moreover, previous studies have revealed that poly-
morphonuclear neutrophils (PMNs) play a prominent
inflammatory role in atherogenesis in humans [7], mice
[8] and pigs [9]. An earlier study has found PMNs in
human tissues at lesions of plaque rupture and erosion,
or in thrombi from acute coronary syndrome patients
[10]. Previous studies have hypothesized that the num-
ber of PMNs in circulation, and the amount of PMN-
produced elastase and myeloperoxidase (MPO) correlate
with atherosclerosis [10, 11]. A positive correlation be-
tween peripheral PMN density and myocardial infarction
has also been consistently observed [12].
Earlier studies have reported that human neutrophil
peptides (HNPs) play a role in endothelial cell dysfunc-
tion during early atherosclerotic development. HNPs are
cysteine-rich positively charged polypeptides that are
produced and released from activated PMN granules.
The α-defensin genes, DEFA1 and DEFA3, encode HNP-
1, 2 and 3 [13, 14]. During inflammation, large amounts
of intracellular proteins are released from activated
PMNs into the extracellular milieu as a consequence of
PMN degranulation, leakage during phagosome forma-
tion, and cell death. The highly homologous HNP-1, -2
and -3 make up more than half of the total protein con-
tents within PMN azurophilic granules [15]. Moreover,
HNP 1–3 levels are markedly increased in inflammation,
including sepsis and acute coronary vascular disorders [1].
The present study was a cross-sectional design, with
three male groups, including healthy control subjects, pa-
tients with hyperlipidemia and patients with CHD. These
groups were representative of atherosclerosis development
and CHD complications. Our data demonstrated an asso-
ciation between α-defensin expression levels and CHD de-
velopment. We suggest that this knowledge may be
applied to develop a key inflammatory marker for CHD
risk in Thai hyperlipidemia patients.
Methods
Materials
In this study we used D-PBS (Wisent Inc., Quebec,
Canada), TRIzol® Reagent (Invitrogen™, Carlsbad, CA,
USA), IsoPrep (Robbins Scientific Corporation, Sunnyvale,
CA, USA), RNeasy total RNA kit (Qiagen, Hilden,
Germany), and the Affymetrix GeneChip® Human Gene
1.0 ST Arrays (Affymetrix, Santa Clara, CA, USA). For
qRT-PCR, we designed primers based on previous studies
and Genbank, and had primers synthesized by Pacific
Science Co., Ltd. (Bangkok, Thailand). Human HNP 1–3
enzyme-linked immunosorbent assay (ELISA) reagents
were purchased from Hycult® Biotech (Uden, The
Netherlands). All other reagents were from Sigma-Aldrich
(St. Louis, MO, USA).
Study design and patient population
The study design and characteristics of all volunteers en-
rolled in the study are summarized in Fig. 1. The study
was conducted in the Department of Tropical Medicine,
Mahidol University. Approval for the study was ob-
tained from the Ethics Committees of Faculty of Trop-
ical Medicine, Mahidol University, and Pramongkutklao
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Hospital. All participants were informed of the ob-
jectives of the study and completed an informed
consent form.
All volunteers were unrelated males and born to Thai
parents. All patients were diagnosed, classified and
treated by a specialist (KP) at Pramongkutklao Hospital.
Here, we focused our study on two groups of patients
based on their clinical outcomes according to the criteria
of the American Association. The 45 patients examined
included: 1) 24 hyperlipidemia patients with high choles-
terol levels [total cholesterol (TC), LDL and high-density
lipoprotein (HDL)], but with no evidence of vital organ
dysfunction; and 2) 21 CHD patients who had been di-
agnosed and had coronary bypass grafting under KP
supervision. An additional 20 healthy controls were
non-infected, and had no underlying disease or
cardiovascular risk factors. The age distribution did not
significantly differ between the groups. Before inclusion,
all healthy volunteers and hyperlipidemia patients had
not received any cholesterol or blood pressure-lowering
medication. CHD patients were enrolled before coronary
bypass grafting by KP.
Blood sample collection
Heparinized blood samples (5 mL) were collected
once from healthy donors and from all patients before
hyperlipidemia treatment or coronary bypass grafting.
Plasma (2 mL) was immediately collected by centrifuga-
tion of whole blood, and an aliquot for lipid measurement
was kept at −70 °C for detection of HNP 1–3 by
ELISA (Hycult Biotech). Packed blood cells were re-
suspended in D-PBS (Wisent Inc.) and used to isolate
mononuclear cells. Approximately 2 million peripheral
blood mononuclear cells (PBMCs) in TRIzol (Invitrogen™)
were kept at −70 °C for gene expression profiling by
DNA microarray analysis using Affymetrix GeneChip®
Human Gene 1.0 ST. α-defensin expression was vali-
dated by qRT-PCR.
Fig. 1 Experimental design and study population
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Lipid measurement
Lipid markers including TC, TG, HDL cholesterol
(HDL-c) and LDL cholesterol (LDL-c) were analyzed en-
zymatically using kits (Randox Laboratories limited,
Crumlin, UK) and a biochemistry analyzer (Architect CI
16200, Abbott Laboratories, Abbott Park, IL, USA).
Mononuclear cell isolation
PBMCs were separated by Isoprep (Robbins Scientific
Corporation) gradient centrifugation according to the
manufacturer’s recommendation.
PBMC gene expression profiling using DNA microarray
analysis
Total RNA was extracted from PBMCs of hyperlipid-
emia patients and CHD patients who had undergone by-
pass grafting, and of control volunteers (n = 3) using
RNA isolation kits (Qiagen). Total RNA was quantified
using a NanoDrop ND-1000 spectrophotometer with
ND-1000 3.3 software, and RNA integrity (RIN) was ex-
amined using an Agilent Bioanalyzer (Santa Clara, CA,
USA). Affymetrix GeneChip® Human Gene 1.0 ST was
performed using 5 μg of total RNA with RIN ≥ 8.0, ac-
cording to the manufacturer’s protocol (Affymetrix Inc.).
The data were analyzed by Agilent GeneSpring GX
Software version 12.0. Differentially expressed genes
correlating with inflammation were identified using the
criteria of a > 2.0-fold increase/decrease expression in
the two patient groups compared with the control group
[7]. Up-regulated genes common between hyperlipid-
emia and CHD patients, but not with controls were se-
lected to further assess the feasibility of using them as
inflammatory markers of CHD development [16].
Validation of α-defensin DEFA1/DEFA3 expression
Investigation of α-defensin mRNA expression by qRT-PCR
Total RNA was isolated from PBMCs (2 × 106) using Tri-
zol (Invitrogen). cDNA was synthesized using 1 μg of total
RNA with SuperScript III First-Strand Synthesis System
for RT-PCR (Invitrogen), according to the manufacturer’s
protocol. We designed primers based on DEFA1/DEFA3
genes (GenBank accession numbers NM_005217.3). qRT-
PCR was performed in duplicate. Each 20-μl PCR reaction
contained 10 μl of LightCyCler 480 SYBR Green I Master
mix (Roche Diagnostic, Mannheim, Germany) mixed with
100 ng of cDNA and 0.5 μM of each primer (forward: 5′-
TCCTTGCTGCCATTCTCCTG-3′ and reverse: 5′-TG
CACGCTGGTATTCTGCAA-3′). Amplification was con-
ducted in a LightCycler® Real-Time PCR system (Roche
Applied Science, Indianapolis, IN, USA). PCR reactions
were subjected to 95 °C for 5 min, followed by 45 cycles of
denaturation at 95 °C for 30 s, annealing at 60 °C for 30 s,
and melting curve analysis at 65 °C for 1 min. The ex-
pected PCR product size was 204 bp. β-Actin (ACTB)
primers (forward: 5′-TCACCCACACTGTGCCCATCTA
CGA −3′ and reverse: 5′ -CAGCGGAACCGCTCATTG
CCAATGG-3′) were used to normalize the relative ex-
pression level of α-defensin [17]. The 2−(ΔΔCt) method was
used to quantify relative expression levels.
Determination of plasma HNP 1–3 by ELISA
Plasma was centrifuged at 2500 × g for 5 min and HNP
1–3 concentrations were measured by ELISA (Hycult
Biotechnology), according to the manufacturer’s instruc-
tions. Briefly, 100 μl of plasma from the three groups
(n = 17) were diluted 20-fold in sample dilution buffer,
and standards at concentrations of 10,000 to 136 pg/ml
were transferred to microtiter wells coated with the
specific antibody and incubated for 60 min at room
temperature (RT). Each well was then washed to remove
unbound material and biotinylated tracer antibody
(100 μl) was added, followed by incubation for 60 min at
RT. After removing unbound materials, streptavidin-
peroxidase conjugate was added (100 μl/well) and incu-
bated for 60 min at RT. Bound enzyme was detected by
adding 100 μl of tetramethylbenzidine substrate to each
well, and reactions were stopped by adding 100 μl of stop
solution. Optical density was determined at 450 nm using
Tecan Sunrise OEM Remote Microplate Absorbance
Reader (Tecan, Grödig, Austria). HNP 1–3 concentrations
were calculated from the HNP 1–3 standard curves.
Statistical analysis
Clinical data are reported as median (upper and lower
range limits). The amount of α-defensin mRNA is repre-
sented as fold change relative to healthy controls. HNP
1–3 levels were expressed as median ± SEM. The signifi-
cance of the differences between two groups was deter-
mined by the Mann–Whitney U test, and those among
three groups were determined by the Kruskal–Wallis
test. Correlations between CHD development and α-
defensin mRNA expression or plasma HNP 1–3 levels
were analyzed by the Rho-Spearman correlation analysis.
The α level was set at < 0.05 at a 95 % confidence inter-
val. All statistical analyses were performed using SPSS
version 11.5 (SPSS, Chicago, IL, USA).
Results
Clinical manifestations
The baseline characteristics of all patients and healthy con-
trols are summarized in Table 1. The healthy and hyperlip-
idemia patients did not differ in age, whereas the CHD
patients were significantly older compared with the control
and hyperlipidemia groups (both p = 0.000). Hyperlipid-
emia patient TC levels were significantly higher than those
in control (p = 0.003) and CHD patients (p = 0.007).
The TC, LDL-c and HDL-c levels of the CHD group
were not significantly different from those of the
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controls (p > 0.050). However, the hyperlipidemia pa-
tient LDL levels were higher than those in CHD pa-
tients (p = 0.039).
Profiling of hyperlipidemia and CHD patients reveals
common up-regulated genes
We observed nine up-regulated genes (entity list 2) in
the hyperlipidemia group and 40 genes (entity list 1) in
the CHD group (Fig. 2) relative to the baseline by DNA
microarray analysis. Of these, eight genes were common
to both groups of patients (Fig. 1c and d, and Table 2).
Based on these results, we sought to validate α-defensin
(one of eight intersected genes) expression and its asso-
ciation with CHD development.
Increased expression of α-defensin mRNA in hyperlipid-
emia and CHD patients
The relative expression levels of α-defensin mRNA in
healthy, hyperlipidemia and CHD patients are shown in
Fig. 3a. Our findings revealed that α-defensin mRNA ex-
pression (mean 2-fold change) in hyperlipidemia (p = 0.043)
and bypass graft surgery (p = 0.05) patients was increased
compared with controls. Notably, the relative expression
differences between CHD and hyperlipidemia patients were
not significant (p = 0.374).
Increased levels of plasma HNP 1–3 in hyperlipidemia and
CHD patients
There was a trend of increased plasma HNP 1–3 in
hyperlipidemia (p = 0.373) and CHD patients (p = 0.004)
compared with the levels in the healthy volunteers. Fur-
thermore, CHD patients had higher HNP 1–3 levels
than hyperlipidemia patients (p = 0.036; Fig. 3b).
Correlations between clinical manifestation, expression of
DEFA1/DEFA3, HNP 1–3 levels and CHD development
Our cross-sectional study assumed that pathologic
changes progress from normal to hyperlipidemia and fi-
nally to CHD complications. The correlations are shown
in Fig. 4. There was a moderate correlation between
DEFA1/DEFA3 gene expression and HNP plasma levels
(r = 0.536, p = 0.010). Additionally, α-defensin DEFA1/
DEFA3 mRNA expression positively correlated with CHD
development (r = 0.429, p = 0.023). Elevated plasma HNP
1–3 levels were consistently associated with CHD devel-
opment (r = 0.486, p = 0.000), and CHD correlated with
age (r = 0.602, p = 0.005). Lipid profiling revealed a
correlation between plasma HNP 1–3 levels in normal
and hyperlipidemia patients as indicated by TC (r = 0.530,
p = 0.024) and LDL (r = 0.525 p = 0.030), but not by HDL
(r = −0.870, p = 0.714) and TG (r = 0.088, p = 0.721) levels.
Discussion
Our cross-sectional study revealed that CHD develop-
ment is associated with an increase in DEFA1/DEFA3
mRNA expression and plasma HNP 1–3 levels. Based
on these results, we suggest that increased α-defensin
expression has potential as an inflammatory marker for
predicting CHD in hyperlipidemia patients. However, α-
defensin expression as a predictive marker should be
confirmed on a larger patient cohort in a future multi-
center study, to validate these observations.
Previous cross-sectional studies covered a shorter ob-
servation time and were more appropriate for under-
standing the long-term development from initiation to
complete pathogenesis [18–22]. Similarly, we profiled
the expression of control, hyperlipidemia and CHD
groups that are representative of the development of
atherosclerosis to CHD (Fig 1).
In this preliminary study, we chose only male volun-
teers to control the influence of the sex-hormone factor.
Estrogens are primary examples of female sex steroids.
Epidemiological studies in animal models, e.g., rabbits,
mice, and monkeys, have shown that estrogen has pro-
tective effects in cardiovascular disease. Previous evi-
dence has also suggested that estrogen protects women
against CHD pre-menopause (reviewed in [23]). We ex-
pect that the results of this study will help further stud-
ies find appropriate biomarkers to predict CHD in both
male and female Thai hyperlipidemia patients.




(H) n = 17
Coronary
Heart Disease
(CHD) n = 17
p values
N vs. H H vs. CHD N vs. CHD
Age (years) 42 (23–58) 42 (26–58) 66 (58–78) 0.608 0.000 0.000
TC (mg/dL) 174.5 (156–199) 223 (150–304) 166 (115–259) 0.004 0.008 0.653
TG (mg/dL) 147 (70–162) 166 (103–1181) 92 (72–169) 0.759 0.013 0.025
HDL (mg/dL) 41 (31–56) 45.5 (26–80) 49 (37–75) 0.213 0.496 0.063
LDL (mg/dL) 99 (60–111) 130.5 (63–190) 89 (44–174) 0.072 0.049 0.323
All patients and controls were male. N normal controls, H and CHD patients with hyperlipidemia and coronary heart disease, respectively
Data are shown as medians (ranges). The differences in each variable between two groups (N vs. H, H vs. CHD, and N vs. CHD) were determined using the Mann–Whitney U
test. The α level was set at < 0.05 at a 95 % confidence interval. The significantly different variables between groups are shown by p value in bold
TC total cholesterol, TG triglyceride, HDL high-density lipoprotein, LDL low-density lipoprotein
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Fig. 2 (See legend on next page.)
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Blood is an accessible source for diagnosing disease
processes in disorders such as autoimmune disease,
asthma and breast cancer [24]. Blood is a particularly fit-
ting surrogate for atherosclerotic tissue, because it con-
tains inflammatory cells, which play an important role in
atherogenesis [1]. Consistent with this knowledge, previ-
ous studies used PBMC expression profiling to study the
pathogenesis, diagnosis and pharmacokinetics in human
atherosclerosis, stroke and other vascular diseases
[24–26]. These approaches are consistent with our study,
which used PBMCs from healthy, hyperlipidemia and
CHD patients to investigate expression differences associ-
ated with atherosclerosis and CHD complications.
In this study, we designed the DEFA1/DEFA3 qRT-PCR
primers based on DEFA1/DEFA3 genes (GenBank acces-
sion numbers NM_005217.3) and examined primers and
target using primer blast from the NCBI website. The pri-
mer blast analysis showed that the DEFA1/DEFA3 primers
in our study completely matched (100 %) the DEFA1/
DEFA3 genes (NM_005217.3) and other variant defensin
alpha genes in the NCBI database: 1. Homo sapiens
defensin, alpha 3, neutrophil-specific (DEFA3), tran-
script variant X1, mRNA (XM_011534741.1), 2. Homo
sapiens defensin, alpha 1 (DEFA1), transcript variant X3,
mRNA (XM_011534740.1), 3. Homo sapiens defensin
alpha 1B (DEFA1B), transcript variant 1, mRNA
(NM_001302265.1), 4. Homo sapiens defensin alpha 1
(DEFA1), mRNA (NM_004084.3), and 5. Homo sapiens
defensin alpha 1B (DEFA1B), transcript variant 2, mRNA
(NM_001042500.1)
The PCR product size of this gene was 204 bp, as calcu-
lated by this program. Our DEFA1/DEFA3 primers were
optimized and the size of target product determined by
conventional PCR method and gel electrophoresis, re-
spectively. We found a single band of PCR product of
about 200 bp. In addition, all PCR products from qRT-
PCR, which amplified with the DEFA1/DEFA3 qRT-PCR
primers, were confirmed by gel electrophoresis. Those
PCR products showed the same size as expected. The
DEFA1/DEFA3 qRT-PCR primers were predicted to hit
homo sapiens DEAH-box helicase 8 (DHX8) gene. How-
ever, both forward and reverse primers did not completely
match the DHX8 sequence, and the PCR product was
clearly different from the expected target product (660 bp).
Therefore, our DEFA1/DEFA3 gene primer is specific
enough and appropriate for qRT-PCR in this study.
For beta actin (ACTB) primers, we followed the pri-
mer sequences from previous studies [17, 27]. Using pri-
mer blast from the NCBI website, this ACTB primer set
was predicted to hybridize the same region with both
human ACTB gene and a part of the POTE gene family.
Although the nucleotide sequence of the actin part of
the POTE gene family and human beta actin are similar,
the POTE gene family is expressed in many cancers, but
restricted to a few in normal reproductive tissues (pros-
tate, testes, ovaries, and placenta) [28–30]. In this study,
we determined gene expression from the PBMC of
hyperlipidemia, CHD patients, and normal volunteers
with no underlying disease. Therefore, no target for the
POTE gene family could interfere in the present study.
Similarly, some earlier studies used the ACTB primer
from a similar region to our study. These primer sets
were also predicted to amplify the POTE gene family
[31, 32]. In addition our study using ACTB as a house
keeping gene was in agreement with previous studies re-
lated to α − defensin gene expressions in other diseases
[33–35] and other gene expression [17]. We suggest
these ACTB primers were appropriate for normalizing
the relative expression level of the DEFA1/DEFA3 gene.
DNA microarray analysis revealed that DEFA1/DEFA3
are expressed in both hyperlipidemia and CHD patients
(Fig. 2). Our results showed that DEFA1/DEFA3 mRNA
expression was not significantly different between these
groups (p > 0.05; Fig. 3a), i.e., DEFA1/DEFA3 expression
was similar between hyperlipidemia and CHD patients.
(See figure on previous page.)
Fig. 2 Gene expression profiling by DNA microarrays. a and b Heat maps of differentially expressed transcripts in peripheral blood mononuclear
cells (PBMCs) from coronary heart disease (CHD) patients post coronary bypass grafting vs. control a and hyperlipidemia patients vs. control b.
Total RNA was extracted from 2 million PBMCs (n = 7). Differentially expressed genes > 2.0-fold were further evaluated: c Venn diagram illustrating
the eight genes up-regulated in the two patient groups; d List of the eight genes common to both patient groups
Table 2 Profiles of intersected up-regulated genes in
hyperlipidemia and CHD patients
Gene symbol Gene description
HBB hemoglobin beta
HBA2/HBA1 hemoglobin alpha2/hemoglobin alpha1
IL-1-beta Interleukin-1 beta
SOD2 superoxide dismutase 2, mitochondrial
PPBP pro-platelet basic protein (chemokine
C-X-C motif ligand 7)
DEFA3|DEFA1|DEFA1B defensin alpha 3, neutrophil-specific |
defensin alpha 1 | defensin alpha 1B
CCL3 chemokine (C-C motif) ligand 3, macrophage
inflammatory protein 1 alpha
CCL4 chemokine (C-C motif) ligand 4, macrophage
inflammatory protein 1 beta
The gene in bold was selected as a focus that was validated using qRT-PCR
and ELISA
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Therefore, we suggest that DEFA1/DEFA3 may serve as
a biomarker for CHD development in hyperlipidemia
patients.
The highest HNP 1–3 concentrations were found in
CHD patients (Fig. 3b), and differences were observed in
HNP 1–3 levels between CHD and hyperlipidemia pa-
tients (p = 0.036), and healthy controls (p = 0.004). These
elevated HNP 1–3 levels may be the consequence of the
degranulation of neutrophils recruited from atheroscler-
otic plaques [2].
Our findings revealed a correlation between HNP 1–3
levels and TC (r = 0.530, p = 0.024) and LDL (r = 0.525
p =0.030) levels, but not TG (r = 0.525 p =0.030) or
HDL (r = −0.870, p = 0.714; Fig. 4) levels. These ob-
servations are in line with a previous study on hu-
man patients [36] and an in vitro study [37].
Moreover, an earlier murine model, lacking HNP ex-
pression, suggests that HNP and LDL play equally
important roles in the pathogenesis of vascular dis-
ease [38]. Collectively, these findings are in agreement
Fig. 3 Expression of α-defensin and HNP 1–3. a α-Defensin mRNA expression (2-fold changes) relative to β-actin mRNA in PBMCs obtained from
healthy controls, and hyperlipidemia and CHD patients post graft bypass surgery, as determined by qRT-PCR. Data are presented as the mean
2-fold change relative to control ± SEM (n = 10). b Plasma levels of HNP 1–3 (pg/ml) from healthy controls, hyperlipidemia patients and CHD
patients post graft bypass surgery. Data are presented as mean ± SEM (n = 17). One-way ANOVA followed by Scheffe’s post hoc test for statistical
significance of mRNA expression and HNP levels (p < 0.05) were used for statistical comparisons
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with our results. CHD patients underwent coronary
bypass grafting. Therefore, the TC, LDL and TG levels of
these patients were significantly lower than those of
hyperlipidemia patients, and similar to those of control
patients. Interestingly, we observed that the TC and LDL
levels decreased to normal ranges following administra-
tion of the appropriate lipid-lowering medication, while
the HNP 1–3 levels remained elevated compared with
the control and hyperlipidemia patients (Fig. 3b). We
suggest that chronic neutrophil recruitment to athero-
sclerotic plaques in the vasculature of CHD patients
was not inhibited by lipid-lowering drugs. Therefore,
the highest HNP levels were found in the CHD
group. Moreover, our findings on HNP expression
provide new insight into CHD pathogenesis, which
may affect future applications.
In contrast to a murine model [38], α-defensin in a por-
cine model reduced EC-dependent vasorelaxation. This
effect is associated with increased superoxide radical pro-
duction and decreased endothelial nitric oxide synthase
(eNOS) expression in porcine coronary arteries [9].
Earlier studies have found discrepancies in HNP levels
in sera [39–41], plasma [42] or biological fluids [41] of
normal and various diseases including infectious diseases
[41, 43, 44], metabolic diseases (e.g., diabetes) [45, 46],
cardiovascular disease [2, 47], cancers of urinary bladder
[42], colorectal cancer [40], colorectal adenoma [48] and
colon carcinoma [39]. It has been reported that normal
plasma levels of HNPs range from undetectable to 50–
100 ng/ml. Similarly, our findings showed that normal
HNPs’ levels ranged from undetectable to 10 ng/ml
(Fig. 3b). Earlier studies have found that at the onset of
Fig. 4 Correlations between plasma HNP 1–3 levels and age a TC b LDL c HDL d and TG e and correlation between relative expression of
DEFA1/DEFA3 and HNP 1–3 levels f. Note: Results in a and f were analyzed among the three groups; in b–e patients with CHD were excluded,
because they used lipid-lowering drugs
Maneerat et al. Lipids in Health and Disease  (2016) 15:117 Page 9 of 12
bacterial infection and during nonbacterial infection, the
mean HNP levels were 2- to 4-fold of those in healthy
volunteers [43]. In bacterial meningitis, plasma HNP
levels in sepsis patients ranged from 900 to 170,000 ng/ml
compared with a mean of 42–53 ng/ml in the plasma of
healthy controls [44].
We found that the increased levels of HNP 1–3 were
moderately associated with DEFA1/DEFA3 expression
(r = 0.536, p = 0.010). Previous studies have reported
increased levels of HNPs in inflammatory diseases, indi-
cating that HNPs play a critical role in the leukocyte-
dominant proinflammatory responses that may contribute
to cardiovascular disorders [49, 50] and bacterial meningi-
tis [44]. Moreover, it has been reported that HNP deposits
in skin biopsies are a strong independent predictor of cor-
onary artery disease [41]. This suggested a link between
PMN activation and progression of atherosclerosis, and
provided a novel approach to assess the risk of coronary
artery disease.
There is a correlation between HNP concentration and
the number of blood PMNs in patients with inflamma-
tory diseases [43]. Previous studies have reported a posi-
tive correlation between the peripheral PMN count and
myocardial infarction [12]. However, we lacked data on
the number of circulating neutrophils and the associ-
ation between DEFA1/DEFA3 gene copy numbers and
HNP 1–3 levels. Nevertheless, we assumed that the in-
creased HNP levels, which are the main proteins in
PMN granules, may correlate with PMN levels. In con-
trast, Nemeth et al. have reported that the copy number
did not correlate with gene expression [45].
Quinn et al. have suggested a possible mechanism of
action by which HNPs mediate cardiovascular disease.
HNP 1–3 modulate the development of atherosclerosis
by increasing the binding of LDL to the EC surface, pro-
moting accumulation of LDL in the vasculature and
inhibiting fibrinolytic activity on the surface of vascular
cells accumulating in atherosclerotic plaques [2]. More-
over, HNPs form stable, multivalent complexes with
LDL [37], both in solution and on the cell surface [37].
They also stimulate the binding of 125I-labeled LDL to
human umbilical vein endothelial cells (HUVECs),
smooth muscle cells and fibroblasts in a dose-dependent
and saturable manner [37]. Additionally, it has been
proposed that HNP-LDL complexes bind to heparin
sulfate-containing proteoglycans (HSPG) [37]. The LDL
receptor-related protein (LRP)/-2 macroglobulin receptor is
a membrane protein of the LDL receptor (LDLR) super-
family [51] involved in atherogenesis [52, 53]. Increased ex-
pression of LRP has been demonstrated in vascular smooth
muscle cells isolated from human atherosclerotic lesions
[54]. LRP1 gene expression is also increased in blood
mononuclear cells from patients with myocardial infarction
[51]. An earlier study has demonstrated that HNPs directly
bind LRP both in solution and on the surface of smooth
muscle cells [55]. The structure of HNPs, with a hydropho-
bic and cationic site, is similar to many apolipoproteins that
bind to LDLR family members and proteoglycans [37].
Hence, the ability of HNPs to modulate the catabolism of
LDL may occur through similar mechanisms [37]. How-
ever, because many molecules (e.g., ApoE, thrombospondin,
protein C, tPA, thrombin) are also ligands of LRP, the bio-
logical consequences of HNP and LRP binding remain to
be investigated in the pathogenesis of atherosclerosis [51].
A previous study [29] used an ApoE−/− mouse model,
which is important for studying the mechanisms by
which LDL, as a sole mediator, induces atherosclerosis.
Murine PMNs lack HNPs, which raises the question of
the importance of HNPs in the atherosclerotic pathology
observed in ApoE−/− mice. The study has demonstrated
that the HNP-mediated inflammatory responses and the
direct effects of LDL on the pathogenesis of cardiovascu-
lar diseases are equally important. PMN infiltration in
chronic arterial inflammation, and the pivotal role of
PMN contributing to atherogenesis was supported by a
decrease in the atherosclerotic burden when PMNs were
depleted in ApoE−/− mice [29].
Our cross-sectional findings demonstrated increased
expression of α-defensin during CHD development.
Therefore, this could be indirectly interpreted as an im-
portant role for neutrophils in the development of ath-
erosclerosis and consequently CHD. In contrast, our
study indicated that DEFA1/DEFA3 mRNA expression
and plasma HNP levels were consistent, hence they
should be considered for further cross-sectional or larger
cohort studies, including more randomized population
groups, to elucidate the feasibility of predictive CHD
biomarkers. We found a moderate correlation between
HNP expression and disease development. This suggests
that there may be more appropriate predictive markers
that could lead to more reliable prediction of CHD.
Additional studies are needed to validate whether add-
itional genes (Table 2) are appropriate as inflammatory
predictive markers for the risk of CHD development in
Thai populations.
Limitations
This study has some limitations. First, our sample size
was small due to a limited budget. Statistical bias might
occur. Further studies with a larger sample size and al-
ternative simple techniques to detect markers are
needed to confirm the current hypothesis. In addition,
longitudinal studies are clearly needed to better define
the importance of α-defensin expression. However, the
hyperlipidemia and CHD groups significantly differ in
age; thus, a longer observation period is needed for a co-
hort study. In this study we did not examine the α-
defensin mRNA expression and plasma HNP 1–3 levels
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in medical treatment hyperlipidemia and CHD patients,
which would provide more evidences to support our hy-
pothesis. The effect of drugs on decreasing cholesterol
levels is a very interesting factor, but was considered ex-
cessively complex for inclusion in the present study.
Various lipid-lowering drugs are used, with different
modes of action. Further studies with larger sample sizes
would be more appropriate to assess the effects of these
drugs on the development of CHD. Furthermore, the ab-
sence of neutrophil numbers and DEFA1/DEFA3 copy
number is another limitation.
Conclusions
Taken together, our findings suggest that hyperlipidemia
patients with elevated TC and/or LDL levels in combin-
ation with increased α-defensin mRNA expression and/
or elevated plasma HNP levels may be at risk of devel-
oping CHD.
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